Enveric Biosciences, Inc.

NasdaqCM ENVB

Enveric Biosciences, Inc. Price to Sales Ratio (P/S) on February 05, 2025

Enveric Biosciences, Inc. Price to Sales Ratio (P/S) is NA on February 05, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Enveric Biosciences, Inc. 52-week high Price to Sales Ratio (P/S) is NA on February 05, 2025, which is NA below the current Price to Sales Ratio (P/S).
  • Enveric Biosciences, Inc. 52-week low Price to Sales Ratio (P/S) is NA on February 05, 2025, which is NA below the current Price to Sales Ratio (P/S).
  • Enveric Biosciences, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is NA.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
SV Wall Street
NasdaqCM: ENVB

Enveric Biosciences, Inc.

CEO Dr. Joseph Edward Tucker Ph.D.
IPO Date May 4, 2015
Location United States
Headquarters 4851 Tamiami Trail North
Employees 7
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Mental Health Personal Care Tobacco
Description

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Similar companies

ZURA

Zura Bio Limited

USD 1.78

4.09%

StockViz Staff

February 6, 2025

Any question? Send us an email